Algiax announces results from phase 2a trial for neuropathic pain treatment

Study shows AP-325 offers lasting pain relief without central side effects

Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain, has released positive topline data from its phase 2a clinical trial of AP-325. The trial results suggest that AP-325, an allosteric GABAA-receptor modulator, rapidly reduces neuropathic pain and provides long-term benefits.

Neuropathic pain is a chronic condition linked to an imbalance in neuronal signals. AP-325 aims to reduce pain by activating GABAA signalling, counteracting excessive neuronal activity. The trial showed AP-325’s potential to transform neuropathic pain management.

Dr Ingo Lehrke, CEO of Algiax Pharmaceuticals, commented: “These results mark a significant step towards our vision of disarming chronic neuropathic pain and offering a well-tolerated treatment option without the risk of dependence.”

Key findings include a rapid onset of action and meaningful pain reduction within less than two weeks. Treatment effects remained persistent, suggesting lasting disease modification, with over a quarter of patients showing a pain reduction of ≥50% and more than half of the patients did not need rescue medication.

The number needed to treat (NNT) compared favourably to the current standard of care. There was significant improvement in sleep quality and reduction in anxiety and depression, and the safety profile was good, with side effects comparable to placebo and no central side effects.

Dr Guido Koopmans, CSO of Algiax Pharmaceuticals, noted: “The clinical meaningful effects and clean safety profile underline AP-325’s potential to provide a paradigm shift in neuropathic pain management.”

The phase 2a trial enrolled 99 participants in Germany, Spain, the Czech Republic, Belgium and France. The study evaluated AP-325 as a monotherapy for peripheral post-surgical neuropathic pain.